RARE News

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

Robbins LLP Recommends That RARE Investors Who Incurred Significant Losses Contact The Firm For Information About Leading The Ultragenyx Pharmaceutical Inc. Class Action

RARE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026

Pomerantz LLP Advises of Securities Class Action Involving Ultragenyx Pharmaceutical Inc. - RARE

RARE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

ROSEN, A LONGSTANDING FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines - RARE

Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – RARE

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update